
SNYR Stock Forecast & Price Target
SNYR Analyst Ratings
Bulls say
Synergy CHC is a well-positioned, consumer-branded health and wellness company with strong growth potential in both its current product offerings and expansion into new markets and products. The company's solid balance sheet, with $3 million in cash and $27 million in debt, provides stability and potential for future investments to drive further growth. The current undervaluation of the stock, coupled with new product developments and strong international growth, make Synergy CHC an attractive investment opportunity with a BUY rating and a raised price target of $5.50, representing significant upside potential from its current share price.
Bears say
Synergy CHC is facing challenges with profitability and sales in Q1 and Q4, leading to a significant drop in share price. Despite growth prospects and an undervalued stock, there are risks such as competition and changes in consumer demands that could affect the company's performance. The recent termination of a distribution deal also impacts revenue and profitability. As a result, it is advisable to exercise caution when investing in Synergy CHC's stock.
This aggregate rating is based on analysts' research of Synergy CHC Corp and is not a guaranteed prediction by Public.com or investment advice.
SNYR Analyst Forecast & Price Prediction
Start investing in SNYR
Order type
Buy in
Order amount
Est. shares
0 shares